Cargando…
A role for eukaryotic initiation factor 4B overexpression in the pathogenesis of diffuse large B-cell lymphoma
Dysregulated expression of factors that control protein synthesis is associated with poor prognosis of many cancers, but the underlying mechanisms are not well defined. Analysis of the diffuse large B-cell lymphoma (DLBCL) translatome revealed selective upregulation of mRNAs encoding anti-apoptotic...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4017261/ https://www.ncbi.nlm.nih.gov/pubmed/24135829 http://dx.doi.org/10.1038/leu.2013.295 |
_version_ | 1782479938588246016 |
---|---|
author | Horvilleur, E Sbarrato, T Hill, K Spriggs, R V Screen, M Goodrem, P J Sawicka, K Chaplin, L C Touriol, C Packham, G Potter, K N Dirnhofer, S Tzankov, A Dyer, M J S Bushell, M MacFarlane, M Willis, A E |
author_facet | Horvilleur, E Sbarrato, T Hill, K Spriggs, R V Screen, M Goodrem, P J Sawicka, K Chaplin, L C Touriol, C Packham, G Potter, K N Dirnhofer, S Tzankov, A Dyer, M J S Bushell, M MacFarlane, M Willis, A E |
author_sort | Horvilleur, E |
collection | PubMed |
description | Dysregulated expression of factors that control protein synthesis is associated with poor prognosis of many cancers, but the underlying mechanisms are not well defined. Analysis of the diffuse large B-cell lymphoma (DLBCL) translatome revealed selective upregulation of mRNAs encoding anti-apoptotic and DNA repair proteins. We show that enhanced synthesis of these proteins in DLBCL is mediated by the relief of repression that is normally imposed by structure in the 5′-untranslated regions of their corresponding mRNAs. This process is driven by signaling through mammalian target of rapamycin, resulting in increased synthesis of eukaryotic initiation factor (eIF) 4B complex (eIF4B), a known activator of the RNA helicase eIF4A. Reducing eIF4B expression alone is sufficient to decrease synthesis of proteins associated with enhanced tumor cell survival, namely DAXX, BCL2 and ERCC5. Importantly, eIF4B-driven expression of these key survival proteins is directly correlated with patient outcome, and eIF4B, DAXX and ERCC5 are identified as novel prognostic markers for poor survival in DLBCL. Our work provides new insights into the mechanisms by which the cancer-promoting translational machinery drives lymphomagenesis. |
format | Online Article Text |
id | pubmed-4017261 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-40172612014-05-13 A role for eukaryotic initiation factor 4B overexpression in the pathogenesis of diffuse large B-cell lymphoma Horvilleur, E Sbarrato, T Hill, K Spriggs, R V Screen, M Goodrem, P J Sawicka, K Chaplin, L C Touriol, C Packham, G Potter, K N Dirnhofer, S Tzankov, A Dyer, M J S Bushell, M MacFarlane, M Willis, A E Leukemia Original Article Dysregulated expression of factors that control protein synthesis is associated with poor prognosis of many cancers, but the underlying mechanisms are not well defined. Analysis of the diffuse large B-cell lymphoma (DLBCL) translatome revealed selective upregulation of mRNAs encoding anti-apoptotic and DNA repair proteins. We show that enhanced synthesis of these proteins in DLBCL is mediated by the relief of repression that is normally imposed by structure in the 5′-untranslated regions of their corresponding mRNAs. This process is driven by signaling through mammalian target of rapamycin, resulting in increased synthesis of eukaryotic initiation factor (eIF) 4B complex (eIF4B), a known activator of the RNA helicase eIF4A. Reducing eIF4B expression alone is sufficient to decrease synthesis of proteins associated with enhanced tumor cell survival, namely DAXX, BCL2 and ERCC5. Importantly, eIF4B-driven expression of these key survival proteins is directly correlated with patient outcome, and eIF4B, DAXX and ERCC5 are identified as novel prognostic markers for poor survival in DLBCL. Our work provides new insights into the mechanisms by which the cancer-promoting translational machinery drives lymphomagenesis. Nature Publishing Group 2014-05 2013-11-01 /pmc/articles/PMC4017261/ /pubmed/24135829 http://dx.doi.org/10.1038/leu.2013.295 Text en Copyright © 2014 Macmillan Publishers Limited http://creativecommons.org/licenses/by-nc-sa/3.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/ |
spellingShingle | Original Article Horvilleur, E Sbarrato, T Hill, K Spriggs, R V Screen, M Goodrem, P J Sawicka, K Chaplin, L C Touriol, C Packham, G Potter, K N Dirnhofer, S Tzankov, A Dyer, M J S Bushell, M MacFarlane, M Willis, A E A role for eukaryotic initiation factor 4B overexpression in the pathogenesis of diffuse large B-cell lymphoma |
title | A role for eukaryotic initiation factor 4B overexpression in the pathogenesis of diffuse large B-cell lymphoma |
title_full | A role for eukaryotic initiation factor 4B overexpression in the pathogenesis of diffuse large B-cell lymphoma |
title_fullStr | A role for eukaryotic initiation factor 4B overexpression in the pathogenesis of diffuse large B-cell lymphoma |
title_full_unstemmed | A role for eukaryotic initiation factor 4B overexpression in the pathogenesis of diffuse large B-cell lymphoma |
title_short | A role for eukaryotic initiation factor 4B overexpression in the pathogenesis of diffuse large B-cell lymphoma |
title_sort | role for eukaryotic initiation factor 4b overexpression in the pathogenesis of diffuse large b-cell lymphoma |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4017261/ https://www.ncbi.nlm.nih.gov/pubmed/24135829 http://dx.doi.org/10.1038/leu.2013.295 |
work_keys_str_mv | AT horvilleure aroleforeukaryoticinitiationfactor4boverexpressioninthepathogenesisofdiffuselargebcelllymphoma AT sbarratot aroleforeukaryoticinitiationfactor4boverexpressioninthepathogenesisofdiffuselargebcelllymphoma AT hillk aroleforeukaryoticinitiationfactor4boverexpressioninthepathogenesisofdiffuselargebcelllymphoma AT spriggsrv aroleforeukaryoticinitiationfactor4boverexpressioninthepathogenesisofdiffuselargebcelllymphoma AT screenm aroleforeukaryoticinitiationfactor4boverexpressioninthepathogenesisofdiffuselargebcelllymphoma AT goodrempj aroleforeukaryoticinitiationfactor4boverexpressioninthepathogenesisofdiffuselargebcelllymphoma AT sawickak aroleforeukaryoticinitiationfactor4boverexpressioninthepathogenesisofdiffuselargebcelllymphoma AT chaplinlc aroleforeukaryoticinitiationfactor4boverexpressioninthepathogenesisofdiffuselargebcelllymphoma AT touriolc aroleforeukaryoticinitiationfactor4boverexpressioninthepathogenesisofdiffuselargebcelllymphoma AT packhamg aroleforeukaryoticinitiationfactor4boverexpressioninthepathogenesisofdiffuselargebcelllymphoma AT potterkn aroleforeukaryoticinitiationfactor4boverexpressioninthepathogenesisofdiffuselargebcelllymphoma AT dirnhofers aroleforeukaryoticinitiationfactor4boverexpressioninthepathogenesisofdiffuselargebcelllymphoma AT tzankova aroleforeukaryoticinitiationfactor4boverexpressioninthepathogenesisofdiffuselargebcelllymphoma AT dyermjs aroleforeukaryoticinitiationfactor4boverexpressioninthepathogenesisofdiffuselargebcelllymphoma AT bushellm aroleforeukaryoticinitiationfactor4boverexpressioninthepathogenesisofdiffuselargebcelllymphoma AT macfarlanem aroleforeukaryoticinitiationfactor4boverexpressioninthepathogenesisofdiffuselargebcelllymphoma AT willisae aroleforeukaryoticinitiationfactor4boverexpressioninthepathogenesisofdiffuselargebcelllymphoma AT horvilleure roleforeukaryoticinitiationfactor4boverexpressioninthepathogenesisofdiffuselargebcelllymphoma AT sbarratot roleforeukaryoticinitiationfactor4boverexpressioninthepathogenesisofdiffuselargebcelllymphoma AT hillk roleforeukaryoticinitiationfactor4boverexpressioninthepathogenesisofdiffuselargebcelllymphoma AT spriggsrv roleforeukaryoticinitiationfactor4boverexpressioninthepathogenesisofdiffuselargebcelllymphoma AT screenm roleforeukaryoticinitiationfactor4boverexpressioninthepathogenesisofdiffuselargebcelllymphoma AT goodrempj roleforeukaryoticinitiationfactor4boverexpressioninthepathogenesisofdiffuselargebcelllymphoma AT sawickak roleforeukaryoticinitiationfactor4boverexpressioninthepathogenesisofdiffuselargebcelllymphoma AT chaplinlc roleforeukaryoticinitiationfactor4boverexpressioninthepathogenesisofdiffuselargebcelllymphoma AT touriolc roleforeukaryoticinitiationfactor4boverexpressioninthepathogenesisofdiffuselargebcelllymphoma AT packhamg roleforeukaryoticinitiationfactor4boverexpressioninthepathogenesisofdiffuselargebcelllymphoma AT potterkn roleforeukaryoticinitiationfactor4boverexpressioninthepathogenesisofdiffuselargebcelllymphoma AT dirnhofers roleforeukaryoticinitiationfactor4boverexpressioninthepathogenesisofdiffuselargebcelllymphoma AT tzankova roleforeukaryoticinitiationfactor4boverexpressioninthepathogenesisofdiffuselargebcelllymphoma AT dyermjs roleforeukaryoticinitiationfactor4boverexpressioninthepathogenesisofdiffuselargebcelllymphoma AT bushellm roleforeukaryoticinitiationfactor4boverexpressioninthepathogenesisofdiffuselargebcelllymphoma AT macfarlanem roleforeukaryoticinitiationfactor4boverexpressioninthepathogenesisofdiffuselargebcelllymphoma AT willisae roleforeukaryoticinitiationfactor4boverexpressioninthepathogenesisofdiffuselargebcelllymphoma |